The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.
Introduction
- The pneumococcal vaccine market has witnessed robust growth in recent years.
- Projected growth from $8.47 billion in 2023 to $9.04 billion in 2024 at a CAGR of 6.7%.
Historic Growth Drivers
- Discovery of Streptococcus pneumoniae.
- Public health concern and early vaccination efforts.
- Healthcare advancements and vaccine policy changes.
Expected Growth in the Coming Years
- Forecasted growth to $11.36 billion in 2028 at a CAGR of 5.9%.
- Factors include evolving strains, research and development, and expanded vaccine access.
View More On The Pneumococcal Vaccine Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
Major Trends in the Forecast Period
- Multivalent vaccine development.
- Targeted vaccination strategies.
- Education and awareness campaigns.
Rising Prevalence of Pneumococcal Contamination Drives Market Growth
- Pneumococcal contamination encompasses various infections caused by Streptococcus pneumoniae.
- The vaccine stimulates antibody production to combat these infections.
- Increasing prevalence drives market growth, with significant hospitalization rates reported.
Key Players in the Market
- Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., among others.
- Diverse range of companies contributing to vaccine development and distribution.
Breakthrough in Vaccine Development
- Merck & Co Inc. launched V116 vaccine targeting eight serotypes of Streptococcus pneumoniae.
- V116 demonstrates superior immunogenicity in adult populations.
- FDA designates V116 as a breakthrough therapy, currently in Phase 3 development.
GSK Expands Vaccine Portfolio
- GSK PLC’s acquisition of Affinivax, Inc. expands its vaccine offerings.
- Access to MAPS technologies and 24-valent pneumococcal vaccine candidate.
Market Segmentation
- Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products.
- Route of Administration: Intravenous, Intramuscular, Subcutaneous.
- Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Others.
- End User: Pediatrics, Adults.
Regional Insights
- North America led the market in 2023.
- Asia-Pacific poised for rapid growth in the forecast period.
Conclusion
- The pneumococcal vaccine market shows substantial growth potential driven by increasing contamination prevalence and innovative vaccine development.
- Collaboration among pharmaceutical companies and advancements in vaccine technology are key factors shaping the market’s trajectory.
- With a focus on targeted vaccination strategies and expansion in emerging markets, the future of pneumococcal vaccine market appears promising.
Request A Sample Of The Global Pneumococcal Vaccine Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp